eLifeMicrobiologyPeer-reviewed journal article
Efficacy of the β-lactam\β-lactamase inhibitor combination is linked to WhiB4 mediated changes in redox physiology of Mycobacterium tuberculosis
S. Mishra, P. Shukla, A. Bhaskar, K. Anand, P. Baloni, R. K. Jha, A. K. Mohan, R. S. Rajmani, V. Nagaraja, N. Chandra, A. Singh
Abstract
AimsInhibition of {beta}-lactamase by clavulanate (Clav) sensitizes multi-and extensively drug-resistant Mycobacterium tuberculosis (Mtb) strains towards {beta}-lactams such as amoxicillin (Amox). However, the underlying mechanism of how Mtb responds to Amox-Clav combination (Augmentin; AG) is not characterized.\n\nResultsWe integrated global expression profiling with the protein-protein interaction landscape and generated a genome-scale network of Mtb in response to AG. In addition to specific targets (e.g., peptidoglycan biosynthesis and {beta}-lactamase), the response to AG was also centered on redox-balance, central carbon metabolism (CCM), and respiration in Mtb. We discovered that AG modulates superoxide levels, NADH/NAD+ balance and mycothiol redox potential (EMSH) of Mtb. Higher intra-mycobacterial EMSH potentiates mycobactericidal efficacy of AG, whereas lower EMSH induces tolerance. Further, Mtb responds to AG via a redox-sensitive transcription factor, WhiB4. Mtb{Delta}whiB4 displayed higher expression of genes involved in {beta}-lactam resistance along with those mediating respiration, CCM and redox balance. Moreimportantly, WhiB4 binds to the promoter regions and represses transcription of genes involved in {beta}-lactamase expression in a redox-dependent manner. Lastly, while Mtb{Delta}whiB4 maintained internal EMSH, exhibited greater {beta}-lactamase activity and displayed AG-tolerance, overexpression of WhiB4 induced oxidative shift in EMSH and repressed {beta}-lactamase activity to aggravate AG-mediated killing of drug-sensitive and -resistant strains of Mtb.\n\nInnovation and ConclusionsThis work demonstrate that efficacy of {beta}-lactam\\{beta}-lactamase inhibitor combination can be attenuated by elevating mycobacterial antioxidant capabilities and potentiated by impairing redox buffering capacity of Mtb. The functional linkage between {beta}-lactams, redox balance, and WhiB4 can be exploited to potentiate AG action against drug-resistant Mtb.
- organism: human
- assay: proteomics
- research focus: drug response / drug discovery
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Ethambutol and Meropenem/Clavulanate Synergy Promotes Enhanced Extracellular and Intracellular Killing of Mycobacterium tuberculosis
F. Olivenca, D. Pires, … M. J. Catalao·bioRxiv·Oct 24, 2023
- Collateral sensitivity to β-lactam drugs in drug-resistant tuberculosis is driven by the transcriptional wiring of BlaI operon genes
A. S. Trigos, B. Goudey, … K. Wyres·bioRxiv·Dec 1, 2017
- Comprehensive identification of β-lactam antibiotic polypharmacology in Mycobacterium tuberculosis
Kaylyn L. Devlin, Emily Hutchinson, … Kimberly E. Beatty·ACS Infectious DiseasesPeer-reviewed·Aug 18, 2025
- Effects of CwlM, a peptidoglycan synthesis regulator, on beta-lactam resistance and host-pathogen interactions
Cátia Silveiro, Diana Mortinho, … Maria João Catalão·bioRxiv·Jul 8, 2025
- In vitro and in vivo synergy of Vancomycin and β-lactams against drug-resistant Mycobacterium tuberculosis and Non-tuberculous mycobacteria
Alok Singh, Pradip Malik, … Arunava Dasgupta·bioRxiv·Mar 24, 2025
- Select β-lactam combinations exhibit synergy against Mycobacterium abscessus in vitro
E. Story-Roller, E. Maggioncalda, G. Lamichhane·bioRxiv·Jan 17, 2019